HFpEF: What are the most likely pathophysiological mechanisms involved in the disease
HFpEF: The essentials to know10' education - Aug. 27, 2018 - Carolyn Lam, MD - National Heart Centre Singapore
This video is part of an educational series of four lectures focussed on The Essentials to know about HFpEF. In this module, prof. Carolyn Lam presents six mechanisms that may underlie the pathophysiology of HFpEF. She discusses why these mechanisms may be targeted for therapy.
Video navigation menu
- Hemodynamic targets for HFpEF 01:11
- Targeting pulmonary hypertension and volume overload 03:15
- Prevalence of coronary microvascular dysfunction in HFpEF 04:32
- Therapeutic options to target CMD 08:18
- Mitochondrial and cardiometabolic abnormalities as possible targets 09:09
This educational video is the third part of a series called "HFpEF: The essentials to know" that are aimed to give cardiologists and other health care professionals involved in the management of heart failure a well-balanced expert view on the current state of the art about the disease.
This recording was developed under auspices of PACE-cme in collaboration with IPCCS. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme or IPCCS.
Other topics covered in this series
Other lectures part of this educational series are:
- HFpEF: What is it & size of the problem - Prof. Adriaan Voors, MD, University Medical Center Groningen, The Netherlands
- What is HFpEF & How do we make the diagnosis? - Prof. Barry Borlaug, MD, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA
- Current and future clinical approaches to manage HFpEF - Prof. Burkert Pieske, MD, Charité University Medicine and German Heart Center, Berlin, Germany
Prof. Carolyn Lam is a Senior Consultant of the National Heart Centre, Singapore and Professor of Duke-NUS Cardiovascular Academic Clinical Program. Dr. Lam also works as a cardiologist at the UMC Groningen, The Netherlands. Dr Lam’s clinical sub-specialty is heart failure, and she is recognized globally for her expertise in HFpEF. She also has expertise in women’s cardiovascular disease, hemodynamics, echocardiography, biomarkers and clinical trials.
This educational series is funded by an unrestricted educational grant provided by Novartis.